Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
6 Months Ended |
Sep. 30, 2020 |
Sep. 30, 2019 |
| Cash Flows From Operating Activities: |
|
|
| Net loss |
$ (2,681,273)
|
$ (2,368,305)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| Depreciation and Amortization |
40,746
|
28,338
|
| Accretion of debt discount |
542,428
|
0
|
| Stock Based Compensation |
59,000
|
277,664
|
| Changes in assets and liabilities: |
|
|
| Prepaid expenses and other receivables |
94,059
|
263,022
|
| Inventory |
(125,311)
|
(170,371)
|
| Accounts payable |
(137,999)
|
59,010
|
| Liability due to related party |
(676,560)
|
100,533
|
| Other liabilities and accrued expenses |
(121,357)
|
(52,608)
|
| Net cash used in operating activities |
(3,006,267)
|
(1,862,717)
|
| Cash Flows from Investing Activities: |
|
|
| Capitalized patent costs |
(27,600)
|
(28,310)
|
| Purchase of property and equipment |
(14,032)
|
(133,716)
|
| Net cash (used in) provided by investing activities |
(41,632)
|
(162,026)
|
| Cash Flows from Financing Activities: |
|
|
| Costs incurred in relation to equity financing |
(957,193)
|
(9,575)
|
| Commission paid on note payable |
(325,000)
|
0
|
| Proceeds from issuance of notes |
5,000,000
|
0
|
| Proceeds from issuance of common stock in relation to equity financing |
15,750,672
|
152,492
|
| Proceeds from warrant exercise |
394,475
|
26,000
|
| Repayments of note payable |
(82,555)
|
0
|
| Net cash provided by financing activities |
19,780,399
|
168,917
|
| Net (decrease) increase in cash |
16,732,500
|
(1,855,826)
|
| Effect of exchange rate changes on cash |
110,332
|
(113,723)
|
| Cash at beginning of period |
106,107
|
3,740,664
|
| Cash at end of period |
16,948,939
|
1,771,115
|
| Supplemental disclosure of non-cash financing activities: |
|
|
| Prepayment of equity compensation |
$ 0
|
$ 85,715
|